Key result
Enzyme immunoassay using a novel specific antiserum with a phenyl boric acid column measured mean serum beta-methyldigoxin concentrations of 1.06 ng/mL compared to 1.74 ng/mL with commercial antiserum.
Why the study?
Does an EIA system using a novel specific antiserum with a PBA column more precisely measure unchanged beta-methyldigoxin in digitalized patients compared to commercial antiserum?
Does an EIA system using a novel specific antiserum with a PBA column more precisely measure unchanged beta-methyldigoxin in digitalized patients compared to commercial antiserum?
An EIA system using a novel specific antiserum with a PBA column for pretreatment allows for more precise measurement of unchanged beta-methyldigoxin in patient serum by separating it from metabolites.
Answers are grounded in this paper and cite their sources.
Novel EIA with specific antiserum and PBA column may enable precise unchanged beta-methyldigoxin measurement; hypothesis-generating for therapeutic monitoring.
The authors compared serum beta-methyldigoxin (MDx) levels in digitalized patients by enzyme immunoassay (EIA) using anti-MDx 3'-hemisuccinate BSA antiserum (antiserum-I) with commercial antidigoxin antiserum (antiserum-II). The usefulness of a phenyl boric acid (PBA) column for pretreatment of the serum samples was also investigated. The assay using antiserum-I demonstrated good accuracy and precision in the concentration range of 0.5 to 5 ng/mL. When the specificities of antiserum-I and antiserum-II were assessed by cross-reactivity studies with various related compounds, antiserum-I was much more specific for MDx antiserum-II. Using a phenyl boric acid (PBA) column, MDx, and digoxigenin, which exhibits a negligible cross-reactivity, were separated from serum, including MDx and its metabolites. The recovery tests of MDx using antiserum-I with a PBA column in human serum were satisfactory and no interference of metabolites of MDx was observed. Mean MDx concentrations in serum samples (n = 30) from digitalized patients by EIA using antiserum-I with PBA column, antiserum-I, and antiserum-II were 1.06, 1.30, and 1.74 ng/mL, respectively. These results indicate that our EIA system using antiserum-I with a PBA column for pretreatment of serum samples is useful to more precisely measure the unchanged type of MDx in patients.
No takes yet. Share an insight, caveat, or question.
Higashi et al. (2003) studied Digitalized patients (n=30). Enzyme immunoassay using anti-MDx 3'-hemisuccinate BSA antiserum with a phenyl boric acid column vs. Commercial antidigoxin antiserum was evaluated on Mean serum beta-methyldigoxin (MDx) concentration. Enzyme immunoassay using a novel specific antiserum with a phenyl boric acid column measured mean serum beta-methyldigoxin concentrations of 1.06 ng/mL compared to 1.74 ng/mL with commercial antiserum.
Synapse has enriched 10 related papers. Consider them for comparative context: